Alberto Albanese

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5202537/publications.pdf

Version: 2024-02-01

345 papers	28,042 citations	10351 72 h-index	6282 158 g-index
365 all docs	365 docs citations	365 times ranked	19042 citing authors

#	Article	IF	Citations
1	Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1. Science, 2004, 304, 1158-1160.	6.0	3,060
2	Phenomenology and classification of dystonia: A consensus update. Movement Disorders, 2013, 28, 863-873.	2.2	1,754
3	Consensus statement on the diagnosis of multiple system atrophy. Journal of the Neurological Sciences, 1999, 163, 94-98.	0.3	1,143
4	Rivastigmine for Dementia Associated with Parkinson's Disease. New England Journal of Medicine, 2004, 351, 2509-2518.	13.9	1,111
5	Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain, 2005, 128, 2240-2249.	3.7	963
6	Consensus statement on the diagnosis of multiple system atrophy. Clinical Autonomic Research, 1998, 8, 359-362.	1.4	823
7	Localization of a Novel Locus for Autosomal Recessive Early-Onset Parkinsonism, PARK6, on Human Chromosome 1p35-p36. American Journal of Human Genetics, 2001, 68, 895-900.	2.6	459
8	PINK1 mutations are associated with sporadic early-onset parkinsonism. Annals of Neurology, 2004, 56, 336-341.	2.8	447
9	The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurology, The, 2013, 12, 264-274.	4.9	426
10	The impact of deep brain stimulation on executive function in Parkinson's disease. Brain, 2000, 123, 1142-1154.	3.7	414
11	Analysis of blink rate patterns in normal subjects. Movement Disorders, 1997, 12, 1028-1034.	2.2	394
12	Longâ€term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Movement Disorders, 2010, 25, 578-586.	2.2	382
13	A Comparison of Injections of Botulinum Toxin and Topical Nitroglycerin Ointment for the Treatment of Chronic Anal Fissure. New England Journal of Medicine, 1999, 341, 65-69.	13.9	373
14	Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain, 2010, 133, 2664-2676.	3.7	367
15	Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinsonâ€™s disease. Neurology, 1999, 53, 85-85.	1.5	366
16	EFNS guidelines on diagnosis and treatment of primary dystonias. European Journal of Neurology, 2011, 18, 5-18.	1.7	350
17	Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurology, The, 2012, 11, 429-442.	4.9	343
18	A Comparison of Botulinum Toxin and Saline for the Treatment of Chronic Anal Fissure. New England Journal of Medicine, 1998, 338, 217-220.	13.9	339

#	Article	IF	Citations
19	Levodopa in the treatment of Parkinson's disease: Current controversies. Movement Disorders, 2004, 19, 997-1005.	2.2	331
20	A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. European Journal of Neurology, 2006, 13, 433-444.	1.7	279
21	Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Movement Disorders, 2002, 17, 1371-1374.	2.2	265
22	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	4.9	248
23	Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology, 2003, 62, 259-264.	0.5	220
24	Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon, 2013, 67, 94-114.	0.8	217
25	Red flags for multiple system atrophy. Movement Disorders, 2008, 23, 1093-1099.	2.2	215
26	White Matter Involvement in Idiopathic Parkinson Disease: A Diffusion Tensor Imaging Study. American Journal of Neuroradiology, 2009, 30, 1222-1226.	1.2	215
27	Pain as a Nonmotor Symptom of Parkinson Disease. Archives of Neurology, 2008, 65, 1191-4.	4.9	208
28	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. Movement Disorders, 2010, 25, 2604-2612.	2.2	205
29	Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. European Journal of Human Genetics, 2005, 13, 748-752.	1.4	197
30	Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: An18F-dopa PET study. Annals of Neurology, 2002, 52, 849-853.	2.8	192
31	Botulinum toxin for chronic anal fissure. Lancet, The, 1994, 344, 1127-1128.	6.3	187
32	Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 175-182.	0.9	183
33	Long-term follow up of subthalamic nucleus stimulation in Parkinsonâ€™s disease. Neurology, 2002, 58, 1546-1550.	1.5	180
34	Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurology, The, 2011, 10, 1074-1085.	4.9	178
35	Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. European Journal of Neurology, 2016, 23, 45-52.	1.7	175
36	Some Specific Clinical Features Differentiate Multiple System Atrophy (Striatonigral Variety) From Parkinson's Disease. Archives of Neurology, 1995, 52, 294-298.	4.9	170

#	Article	IF	Citations
37	Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures. Surgery, 2002, 131, 179-184.	1.0	163
38	Dystonia rating scales: Critique and recommendations. Movement Disorders, 2013, 28, 874-883.	2.2	150
39	Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: From the advanced phase towards the late stage of the disease?. Parkinsonism and Related Disorders, 2014, 20, 376-381.	1.1	150
40	Safety and efficacy of botulinum toxin type A following long-term use. European Journal of Neurology, 2006, 13, 35-40.	1.7	149
41	Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure. American Journal of Surgery, 2000, 179, 46-50.	0.9	147
42	Consensus statement on the diagnosis of multiple system atrophy. Journal of the Autonomic Nervous System, 1998, 74, 189-92.	1.9	141
43	Longâ€term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. Movement Disorders, 2009, 24, 1154-1161.	2.2	140
44	A genome-wide association study in multiple system atrophy. Neurology, 2016, 87, 1591-1598.	1.5	139
45	Efficacy of pallidal stimulation in isolated dystonia: a systematic review and metaâ€analysis. European Journal of Neurology, 2017, 24, 552-560.	1.7	139
46	The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology, 2005, 64, 1810-1812.	1.5	136
47	Botulinum Toxin Injections in the Internal Anal Sphincter for the Treatment of Chronic Anal Fissure. Annals of Surgery, 1998, 228, 664-669.	2.1	133
48	Selecting deep brain stimulation or infusion therapies in advanced Parkinsonâ€™s disease: an evidence-based review. Journal of Neurology, 2013, 260, 2701-2714.	1.8	128
49	Searching for the second best graft for coronary artery bypass surgery: a network meta-analysis of randomized controlled trials. European Journal of Cardio-thoracic Surgery, 2015, 47, 59-65.	0.6	128
50	Cognitive outcome 5 years after bilateral chronic stimulation of subthalamic nucleus in patients with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 248-252.	0.9	123
51	Validation of the Italian version of the Movement Disorder Societyâ€"Unified Parkinsonâ€™s Disease Rating Scale. Neurological Sciences, 2013, 34, 683-687.	0.9	123
52	Early DEtection of wEaring off in Parkinson disease: The DEEP study. Parkinsonism and Related Disorders, 2014, 20, 204-211.	1.1	121
53	Bilateral simultaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Journal of Neurosurgery, 1999, 91, 313-321.	0.9	118
54	DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13-36.32 in an Italian family with cranial-cervical or upper limb onset. Annals of Neurology, 2001, 49, 362-366.	2.8	118

#	Article	IF	Citations
55	Aging is associated with a diffuse impairment of forebrain cholinergic neurons. Brain Research, 1990, 508, 51-59.	1.1	117
56	Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon, 2013, 67, 115-128.	0.8	114
57	Organization of the ascending projections from the ventral tegmental area: A multiple fluorescent retrograde tracer study in the rat. Journal of Comparative Neurology, 1983, 216, 406-420.	0.9	111
58	Possible risk factors for primary adult onset dystonia: a case-control investigation by the Italian Movement Disorders Study Group. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 25-32.	0.9	111
59	Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Movement Disorders, 2001, 16, 197-201.	2.2	111
60	Choline acetyltxansferase (CUT) activity Wers in right and left human temporal lobes. Neurology, 1981, 31, 799-799.	1.5	111
61	Zolpidem in Parkinson's disease. Lancet, The, 1997, 349, 1222-1223.	6.3	107
62	Health-related quality of life in multiple system atrophy. Movement Disorders, 2006, 21, 809-815.	2.2	102
63	Park6-linked parkinsonism occurs in several european families. Annals of Neurology, 2002, 51, 14-18.	2.8	98
64	Botulinum neurotoxins for postâ€stroke spasticity in adults: A systematic review. Movement Disorders, 2009, 24, 801-812.	2.2	98
65	Isolated limb dystonia as presenting feature of Parkin disease. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 827-828.	0.9	91
66	Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint. Movement Disorders, 1999, 14, 911-913.	2.2	89
67	The cortical projections of the thalamic intralaminar nuclei, as studied in cat and rat with the multiple fluorescent retrograde tracing technique. Neuroscience Letters, 1981, 26, 5-10.	1.0	83
68	Excessive Daytime Sleepiness in Multiple System Atrophy (SLEEMSA Study). Archives of Neurology, 2011, 68, 223-30.	4.9	83
69	<scp>GBAâ€Related</scp> Parkinson's Disease: Dissection of Genotypeâ€“Phenotype Correlates in a Large Italian Cohort. Movement Disorders, 2020, 35, 2106-2111.	2.2	83
70	The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology, 2005, 64, 1958-1960.	1.5	81
71	Dystonia: diagnosis and management. European Journal of Neurology, 2019, 26, 5-17.	1.7	80
72	Treatable inherited rare movement disorders. Movement Disorders, 2018, 33, 21-35.	2.2	79

#	Article	IF	Citations
73	Mitochondrial dysfunction in Parkinson disease: evidence in mutant PARK2 fibroblasts. Frontiers in Genetics, 2015, 6, 78.	1.1	77
74	Severe constipation in parkinson's disease relieved by botulinum toxin. Movement Disorders, 1997, 12, 764-766.	2.2	75
75	The European Multiple System Atrophy-Study Group (EMSA-SG). Journal of Neural Transmission, 2005, 112, 1677-1686.	1.4	75
76	PINK1heterozygous rare variants: prevalence, significance and phenotypic spectrum. Human Mutation, 2008, 29, 565-565.	1.1	74
77	Is this dystonia?. Movement Disorders, 2009, 24, 1725-1731.	2.2	74
78	Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. Journal of Neurology, 2013, 260, 714-740.	1.8	74
79	Suicidal ideation in a European Huntington's disease population. Journal of Affective Disorders, 2013, 151, 248-258.	2.0	74
80	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 182-192.	4.9	74
81	Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience Letters, 1988, 87, 46-50.	1.0	71
82	Botulinum toxin in the treatment of outlet obstruction constipation caused by puborectalis syndrome. Diseases of the Colon and Rectum, 2000, 43, 376-380.	0.7	71
83	Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: Longâ€term observation. Movement Disorders, 2009, 24, 555-561.	2.2	71
84	Clinical Usefulness of Apomorphine in Movement Disorders. Clinical Neuropharmacology, 1994, 17, 243-259.	0.2	70
85	Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria.. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 59, 144-151.	0.9	70
86	The clinical expression of primary dystonia. Journal of Neurology, 2003, 250, 1145-1151.	1.8	68
87	Impulse control behaviours in patients with Parkinson's disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 562-564.	0.9	68
88	Treatment of Outlet Obstruction Constipation in Parkinson'S Disease With Botulinum Neurotoxin A. American Journal of Gastroenterology, 2003, 98, 1439-1440.	0.2	67
89	Fifteen-Year Experience in Treating Blepharospasm with Botox or Dysport: Same Toxin, Two Drugs. Neurotoxicity Research, 2009, 15, 224-231.	1.3	66
90	Abnormal tactile temporal discrimination in psychogenic dystonia. Neurology, 2011, 77, 1191-1197.	1.5	66

#	Article	IF	Citations
91	Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. Movement Disorders, 2001, 16, 999-1006.	2.2	65
92	Synergistic Control of Protein Kinase CÂ Activity by Ionotropic and Metabotropic Glutamate Receptor Inputs in Hippocampal Neurons. Journal of Neuroscience, 2006, 26, 3404-3411.	1.7	64
93	Conflict-dependent dynamic of subthalamic nucleus oscillations during moral decisions. Social Neuroscience, 2011, 6, 243-256.	0.7	64
94	Inclusion and exclusion criteria for DBS in dystonia. Movement Disorders, 2011, 26, S5-16.	2.2	64
95	Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study group. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 613-619.	0.9	63
96	Levodopa-induced dyskinesias and their management. Journal of Neurology, 2008, 255, 32-41.	1.8	63
97	Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin. Frontiers in Neurology, 2017, 8, 35.	1.1	63
98	Acetylcholinesterase and catecholamine distribution in the locus ceruleus of the rat. Brain Research Bulletin, 1980, 5, 127-134.	1.4	62
99	Botulinum neurotoxin to treat chronic anal fissure: results of a randomized â€˜Botox vs. Dysportâ€™ controlled trial. Alimentary Pharmacology and Therapeutics, 2004, 19, 695-701.	1.9	62
100	In vivo evidence for GABA_A receptor changes in the sensorimotor system in primary dystonia. Movement Disorders, 2011, 26, 852-857.	2.2	61
101	Acute Challenge with Apomorphine and Levodopa in Parkinsonism. European Neurology, 2000, 43, 95-101.	0.6	59
102	Terminology for Preparations of Botulinum Neurotoxins. JAMA - Journal of the American Medical Association, 2011, 305, 89.	3.8	59
103	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. Journal of Neurology, 2015, 262, 2201-2213.	1.8	59
104	Pallidal stimulation for acquired dystonia due to cerebral palsy: beyond 5Âyears. European Journal of Neurology, 2015, 22, 426.	1.7	58
105	Botulinum toxin injected in the gastric wall reduces body weight and food intake in rats. Alimentary Pharmacology and Therapeutics, 2000, 14, 829-834.	1.9	57
106	The diagnostic challenge of primary dystonia: Evidence from misdiagnosis. Movement Disorders, 2010, 25, 1619-1626.	2.2	57
107	Disability and profiles of functioning of patients with Parkinson's disease described with ICF classification. International Journal of Rehabilitation Research, 2011, 34, 141-150.	0.7	57
108	Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients.. Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 693-694.	0.9	53

#	Article	IF	Citations
109	Surgical treatment of Parkinsonâ€™s disease. Journal of the Neurological Sciences, 1999, 167, 1-10.	0.3	53
110	Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease. Neuropsychologia, 2012, 50, 1980-1989.	0.7	53
111	Genomeâ€wide association study in musician's dystonia: A risk variant at the arylsulfatase G locus?. Movement Disorders, 2014, 29, 921-927.	2.2	53
112	Pathological gambling in Parkinson's disease: Subthalamic oscillations during economics decisions. Movement Disorders, 2013, 28, 1644-1652.	2.2	51
113	Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: Behavioural, morphological and biochemical correlates. Neuroscience, 1993, 55, 823-832.	1.1	50
114	Substantia nigra in Parkinsonâ€™s disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurological Sciences, 2014, 35, 753-758.	0.9	50
115	Cognitive decline in Huntington's disease expansion gene carriers. Cortex, 2017, 95, 51-62.	1.1	50
116	Age-dependent loss of cholinergic neurones in basal ganglia of rats. Brain Research, 1988, 455, 177-181.	1.1	48
117	The organization of dopaminergic and non-dopaminergic mesencephalo-cortical neurons in the rat. Brain Research, 1982, 238, 421-425.	1.1	46
118	Non-DYT1 dystonia in a large Italian family.. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 357-360.	0.9	46
119	Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet, The, 1998, 352, 625.	6.3	46
120	Fixed dystonia unresponsive to pallidal stimulation improved by motor cortex stimulation. Neurology, 2007, 68, 875-876.	1.5	46
121	Locus ceruleus somata contain both acetylcholin esterase and norepinephrine: Direct histochemical demonstration on the same tissue section. Neuroscience Letters, 1979, 14, 101-104.	1.0	45
122	Primary torsion dystonia: the search for genes is not over. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 395-397.	0.9	45
123	Analysis of blink rate in patients with blepharospasm. Movement Disorders, 2006, 21, 1225-1229.	2.2	45
124	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. Movement Disorders Clinical Practice, 2020, 7, 920-929.	0.8	45
125	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of â€œorganicâ€•neurology. European Journal of Neurology, 2021, 28, 1752-1758.	1.7	45
126	Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin. Neuropharmacology, 1989, 28, 1089-1097.	2.0	44

#	Article	IF	Citations
127	Expert recommendations for diagnosing cervical, oromandibular, and limb dystonia. Neurological Sciences, 2019, 40, 89-95.	0.9	44
128	A neurophysiological study of myoclonus in patients with DYT11 myoclonusâ€dystonia syndrome. Movement Disorders, 2008, 23, 2041-2048.	2.2	43
129	Mutation screening of the DYT6/THAP1 gene in Italy. Movement Disorders, 2009, 24, 2424-2427.	2.2	43
130	Review article The use of botulinum toxin in the alimentary tract. Alimentary Pharmacology and Therapeutics, 1995, 9, 599-604.	1.9	41
131	The New Classification System for the Dystonias: Why Was It Needed and How Was It Developed?. Movement Disorders Clinical Practice, 2014, 1, 280-284.	0.8	41
132	Phenotypic characterization of DYT13 primary torsion dystonia. Movement Disorders, 2004, 19, 200-206.	2.2	40
133	Clinical and neuropsychological correlates in two brothers with pantothenate kinaseâ€“associated neurodegeneration. Movement Disorders, 2005, 20, 208-212.	2.2	40
134	High frequency stimulation of the subthalamic nucleus is efficacious in Parkin disease. Journal of Neurology, 2005, 252, 208-211.	1.8	40
135	Olfactory dysfunction in Parkinsonism caused by PINK1 mutations. Movement Disorders, 2009, 24, 2350-2357.	2.2	39
136	Deep brain stimulation for movement disorders. Considerations on 276 consecutive patients. Journal of Neural Transmission, 2011, 118, 1497-1510.	1.4	39
137	Cholinergic and non-cholinergic forebrain projections to the interpenduncular nucleus. Brain Research, 1985, 329, 334-339.	1.1	38
138	Botulinum Toxin as a Treatment for Blepharospasm, Spasmodic Torticollis and Hemifacial Spasm. European Neurology, 1992, 32, 112-117.	0.6	38
139	Non-motor effects of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: preliminary physiological results. Neurological Sciences, 2001, 22, 85-86.	0.9	38
140	Outcome predictors, efficacy and safety of Botox and Dysport in the longâ€term treatment of hemifacial spasm. European Journal of Neurology, 2009, 16, 392-398.	1.7	38
141	Relationships between disability, quality of life and prevalence of nonmotor symptoms in Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2012, 18, 35-39.	1.1	38
142	Minimally invasive direct coronary artery bypass improves late survival compared with drug-eluting stents in isolated proximal left anterior descending artery disease: A 10-year follow-up, single-center, propensity score analysis. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 1316-1322.	0.4	38
143	Non-DYT1 early-onset primary torsion dystonia: Comparison with DYT1 phenotype and review of the literature. Movement Disorders, 2006, 21, 1411-1418.	2.2	37
144	Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. European Journal of Neurology, 2007, 14, 66-72.	1.7	37

#	Article	IF	Citations
145	Dystonia and Tremor: The Clinical Syndromes with Isolated Tremor. Tremor and Other Hyperkinetic Movements, 2020, 6, 319.	1.1	37
146	Results by motor cortex stimulation in treatment of focal dystonia, Parkinsonâ€™s disease and post-ictal spasticity. The experience of the Italian Study Group of the Italian Neurosurgical Society. Acta Neurochirurgica Supplementum, 2008, 101, 13-21.	0.5	36
147	Strain-dependent variations in the number of forebrain cholinergic neurons. Brain Research, 1985, 334, 380-384.	1.1	35
148	A Case of Dementia Parkinsonism Resembling Progressive Supranuclear Palsy Due to Mutation in the Tau Protein Gene. Archives of Neurology, 2003, 60, 1454.	4.9	35
149	Spontaneous neuronal activity of the posterior hypothalamus in trigeminal autonomic cephalalgias. Neurological Sciences, 2007, 28, 93-95.	0.9	35
150	Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease. Neurology, 2015, 84, 1669-1672.	1.5	35
151	The Italian Dystonia Registry: rationale, design and preliminary findings. Neurological Sciences, 2017, 38, 819-825.	0.9	35
152	Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases. Translational Neurodegeneration, 2022, 11, .	3.6	35
153	Phenotypic variability of DYT1-PTD: Does the clinical spectrum include psychogenic dystonia?. Movement Disorders, 2002, 17, 1058-1063.	2.2	34
154	PARK6 is a common cause of familial parkinsonism. Neurological Sciences, 2002, 23, s117-s118.	0.9	34
155	Bilateral high frequency subthalamic stimulation in Parkinson's disease: long-term neurological follow-up. Journal of Neurosurgical Sciences, 2003, 47, 119-28.	0.3	33
156	Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity. Neuroscience Letters, 1988, 90, 100-106.	1.0	32
157	STN DBS in PD: Selection criteria for surgery should include cognitive and psychiatric factors. Neurology, 2006, 66, 1799-1800.	1.5	32
158	Dopaminergic therapy and subthalamic stimulation in Parkinsonâ€™s disease: a review of 5-year reports. Journal of Neurology, 2010, 257, 298-304.	1.8	32
159	Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3588-3597.	1.8	32
160	Subclinical sensory abnormalities in unaffected PINK1 heterozygotes. Journal of Neurology, 2008, 255, 1372-1377.	1.8	31
161	Motor features and response to oral levodopa in patients with Parkinsonâ€™s disease under continuous dopaminergic infusion or deep brain stimulation. European Journal of Neurology, 2012, 19, 76-83.	1.7	31
162	Role of the dopamine D5 receptor (DRD5) as a susceptibility gene for cervical dystonia. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 665-666.	0.9	30

#	Article	IF	Citations
163	Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene. Annals of Neurology, 2004, 55, 448-448.	2.8	30
164	Anterior rectocele due to obstructed defecation relieved by botulinum toxin. Surgery, 2001, 129, 524-529.	1.0	29
165	Alphaâ€synuclein gene duplication: Marked intrafamilial variability in two novel pedigrees. Movement Disorders, 2013, 28, 813-817.	2.2	29
166	Italian family with cranial cervical dystonia: Clinical and genetic study. Movement Disorders, 1999, 14, 820-825.	2.2	28
167	Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease. Movement Disorders, 2006, 21, 1232-1235.	2.2	28
168	Targeting the brain: considerations in 332 consecutive patients treated by deep brain stimulation (DBS) for severe neurological diseases. Neurological Sciences, 2012, 33, 1285-1303.	0.9	28
169	Surgery of Parkinson's disease: inclusion criteria and follow-up. Neurological Sciences, 2003, 24, s38-s40.	0.9	27
170	Abnormal gating of somatosensory inputs in essential tremor. Clinical Neurophysiology, 2003, 114, 120-129.	0.7	27
171	How Many Dystonias? Clinical Evidence. Frontiers in Neurology, 2017, 8, 18.	1.1	27
172	Management of cervical dystonia with botulinum neurotoxins and EMG/ultrasound guidance. Neurology: Clinical Practice, 2019, 9, 64-73.	0.8	27
173	Update on dystonia. Current Opinion in Neurology, 2012, 25, 483-490.	1.8	26
174	Epidural premotor cortical stimulation in primary focal dystonia: Clinical and ¹⁸Fâ€fluoro deoxyglucose positron emission tomography open study. Movement Disorders, 2012, 27, 533-538.	2.2	26
175	Quantitative gait analysis in parkin disease: Possible role of dystonia. Movement Disorders, 2016, 31, 1720-1728.	2.2	26
176	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	2.8	26
177	Organization of central nervous system dopaminergic pathways. Journal of Neural Transmission Supplementum, 1986, 22, 3-17.	0.5	26
178	Obsessive-compulsive behaviour and cognitive impairment in a parkinsonian patient after left putaminal lesion.. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 288-289.	0.9	25
179	Neurological features in SARS-CoV-2-infected patients with smell and taste disorder. Journal of Neurology, 2021, 268, 1570-1572.	1.8	25
180	Functional motor phenotypes: to lump or to split?. Journal of Neurology, 2021, 268, 4737-4743.	1.8	25

#	Article	IF	Citations
181	Dystonia and Tremor: The Clinical Syndromes with Isolated Tremor. Tremor and Other Hyperkinetic Movements, 2016, 6, 319.	1.1	25
182	Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. Movement Disorders, 2004, 19, S146-S156.	2.2	24
183	Mood disorder following DBS of the left amygdaloid region in a dystonia patient with a dislodged electrode. Movement Disorders, 2008, 23, 147-150.	2.2	24
184	Transient gender-related effects in Parkinsonâ€™s disease patients with subthalamic stimulation. Journal of Neurology, 2010, 257, 603-608.	1.8	24
185	Identification of a novel primary torsion dystonia locus (DYT13) on chromosome 1p36 in an Italian family with cranial-cervical or upper limb onset. Neurological Sciences, 2001, 22, 95-96.	0.9	23
186	Suicide after successful deep brain stimulation for movement disorders. Neurology, 2005, 65, 499-500.	1.5	23
187	Clinical management of pain and fatigue in Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, S233-S236.	1.1	23
188	VPS35-Based Approach: A Potential Innovative Treatment in Parkinson's Disease. Frontiers in Neurology, 2019, 10, 1272.	1.1	23
189	Tardive lingual dystonia treated with clozapine. Movement Disorders, 1996, 11, 585-586.	2.2	22
190	Cortical myoclonus in childhood and juvenile onset Huntington's disease. Parkinsonism and Related Disorders, 2012, 18, 794-797.	1.1	22
191	Therapeutic advances in dystonia. Movement Disorders, 2015, 30, 1547-1556.	2.2	22
192	Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review. Parkinsonism and Related Disorders, 2016, 32, 108-115.	1.1	22
193	Failure of pallidal deep brain stimulation in DYT12-ATP1A3 dystonia. Parkinsonism and Related Disorders, 2017, 45, 99-100.	1.1	22
194	Demographic and clinical determinants of neck pain in idiopathic cervical dystonia. Journal of Neural Transmission, 2020, 127, 1435-1439.	1.4	22
195	Diagnostic criteria for Parkinson's disease. Neurological Sciences, 2003, 24, s23-s26.	0.9	21
196	Botulinum toxin for the management of adult patients with upper motor neuron syndrome. Toxicon, 2009, 54, 634-638.	0.8	21
197	Differential diagnosis of dystonia. European Journal of Neurology, 2010, 17, 1-8.	1.7	21
198	Idiopathic <scp>Nonâ€taskâ€Specific</scp> Upper Limb Dystonia, a Neglected Form of Dystonia. Movement Disorders, 2020, 35, 2038-2045.	2.2	21

#	Article	IF	Citations
199	Worldwide barriers to genetic testing for movement disorders. European Journal of Neurology, 2021, 28, 1901-1909.	1.7	21
200	Clozapine in Huntington's disease. Neurology, 1995, 45, 1023-1023.	1.5	20
201	Impaired body movement representation in DYT1 mutation carriers. Clinical Neurophysiology, 2008, 119, 1864-1869.	0.7	20
202	Functioning and disability in Parkinson's disease. Disability and Rehabilitation, 2010, 32, S33-S41.	0.9	20
203	Discrepancies in reporting the CAG repeat lengths for Huntington's disease. European Journal of Human Genetics, 2012, 20, 20-26.	1.4	20
204	Smoking cessation before coronary artery bypass grafting improves operative outcomes. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 468-474.	0.4	20
205	NMDA receptor gene variations as modifiers in Huntington disease: a replication study. PLOS Currents, 2011, 3, RRN1247.	1.4	20
206	Genetically determined cholinergic deficiency in the forebrain of C57BL/6 mice. Brain Research, 1994, 637, 181-189.	1.1	19
207	Acute Challenge with Apomorphine in HuntingtonÊ¼s Disease. Clinical Neuropharmacology, 1995, 18, 427-434.	0.2	19
208	Cognitive and psychiatric characterization of patients with Huntington's disease and their at-risk relatives. Neurological Sciences, 2002, 23, s105-s106.	0.9	19
209	Recent developments in clinical trials of botulinum neurotoxins. Toxicon, 2018, 147, 77-83.	0.8	19
210	Severe Barbiturate Withdrawal Syndrome in Migrainous Patients. Headache, 1996, 36, 119-121.	1.8	18
211	Gastrointestinal Smooth Muscles and Sphincters Spasms: Treatment with Botulinum Neurotoxin. Current Medicinal Chemistry, 2003, 10, 603-623.	1.2	18
212	Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?. Parkinsonism and Related Disorders, 2020, 71, 40-43.	1.1	18
213	Retrograde fluorescent neuronal tracing combined with acetylcholinesterase histochemistry. Journal of Neuroscience Methods, 1982, 6, 121-127.	1.3	17
214	Acute Administration of Individual Optimal Dose of Physostigmine Fails to Improve Mnesic Performances in Alzheimers Presenile Dementia. International Journal of Neuroscience, 1983, 18, 143-147.	0.8	17
215	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. Parkinsonism and Related Disorders, 2018, 56, 33-40.	1.1	17
216	Preâ€œoperative evaluations for DBS in dystonia. Movement Disorders, 2011, 26, S17-22.	2.2	16

#	Article	IF	Citations
217	Clinical Reasoning: A case of COVID-19â€“associated pharyngeal-cervical-brachial variant of Guillain-BarrÃ© syndrome. Neurology, 2020, 95, 978-983.	1.5	16
218	Peripheral neuropathy in the course of progressive systemic sclerosis: Light and ultrastructural study. Italian Journal of Neurological Sciences, 1982, 3, 341-348.	0.1	15
219	Onset and progression of primary torsion dystonia in sporadic and familial cases. European Journal of Neurology, 2006, 13, 1083-1088.	1.7	15
220	Impact of nonmotor symptoms on disability in patients with Parkinsonâ€™s disease. International Journal of Rehabilitation Research, 2011, 34, 316-320.	0.7	15
221	Designing Clinical Trials for Dystonia. Neurotherapeutics, 2014, 11, 117-127.	2.1	15
222	Can Trazodone Induce Parkinsonism?. Clinical Neuropharmacology, 1988, 11, 180-182.	0.2	14
223	A study of arm movements in Huntington's disease under visually controlled and blindfolded conditions. Neurological Sciences, 2003, 23, 287-293.	0.9	14
224	Low-Voltage Bilateral Pallidal Stimulation for Severe Meige Syndrome in a Patient With Primary Segmental Dystonia. Operative Neurosurgery, 2010, 67, onsE308.	0.4	14
225	Dystonia: clinical approach. Parkinsonism and Related Disorders, 2007, 13, S356-S361.	1.1	13
226	Choice-option evaluation is preserved in early Huntington and Parkinsonâ€™s disease. NeuroReport, 2011, 22, 753-757.	0.6	13
227	Long-term ventralis intermedius thalamic stimulation for parkinsonian tremor. Italian Registry for Neuromodulation in Movement Disorders. Advances in Neurology, 1999, 80, 631-4.	0.8	13
228	Quantitative pharmacohistochemistry of acetylcholinesterase in neostriatum of inbred strains of mice. Brain Research, 1986, 374, 402-408.	1.1	12
229	Primary Focal Hyperhidrosis in a New Family Not Linked to Known Loci. Dermatology, 2011, 223, 335-342.	0.9	12
230	Subthalamic involvement in monetary reward and its dysfunction in parkinsonian gamblers. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 355-358.	0.9	12
231	Botulinum neurotoxins for the treatment of focal dystonias: Review of rating tools used in clinical trials. Toxicon, 2015, 107, 89-97.	0.8	12
232	Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. European Journal of Neurology, 2016, 23, 772-779.	1.7	12
233	Classifying tremor: Language matters. Movement Disorders, 2018, 33, 3-4.	2.2	12
234	Implementation of the Current Dystonia Classification from 2013 to 2018. Movement Disorders Clinical Practice, 2019, 6, 250-253.	0.8	12

#	Article	IF	Citations
235	DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13--36.32 in an Italian family with cranial-cervical or upper limb onset. Annals of Neurology, 2001, 49, 362-6.	2.8	12
236	A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of 1-dopa, 1-deprenyl and dopaminoagonists. Study design and short term results. Italian Journal of Neurological Sciences, 1992, 13, 735-739.	0.1	11
237	Behavioral and personality features in patients with lateralized Parkinsonâ€™s disease. European Journal of Neurology, 2011, 18, 772-777.	1.7	11
238	Botulinum toxin in motor disorders. Current Opinion in Neurology, 1999, 12, 447-456.	1.8	11
239	Review of disease-modifying drug trials in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 521-529.	0.9	11
240	Postural axial tremor in a patient with cerebellar atrophy. Movement Disorders, 1992, 7, 273-280.	2.2	10
241	Phenotype variability of dystonia in monozygotic twins. Journal of Neurology, 2000, 247, 148-150.	1.8	10
242	Distinguishing scan without evidence of dopaminergic depletion patients with asymmetric resting tremor from Parkinson's disease: A clinical diagnosis of dystonia is required. Movement Disorders, 2010, 25, 2899-2899.	2.2	10
243	Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinsonâ€™s disease. Neurological Sciences, 2012, 33, 847-853.	0.9	10
244	Attentional Networks in Parkinsonâ€™s Disease. Behavioural Neurology, 2013, 27, 495-500.	1.1	10
245	Deep brain stimulation for cervical dystonia. Lancet Neurology, The, 2014, 13, 856-857.	4.9	10
246	Shifting from constant-voltage to constant-current in Parkinsonâ€™s disease patients with chronic stimulation. Neurological Sciences, 2017, 38, 1505-1508.	0.9	10
247	Dystonia Management: What to Expect From the Future? The Perspectives of Patients and Clinicians Within DystoniaNet Europe. Frontiers in Neurology, 2021, 12, 646841.	1.1	10
248	EXTRAPYRAMIDAL SYSTEM, MOTOR GANGLIA AND MOVEMENT DISORDERS. Reviews in the Neurosciences, 1990, 2, 145-64.	1.4	9
249	Rivastigmine in Parkinsonâ€™s disease dementia. Expert Review of Neurotherapeutics, 2008, 8, 1181-1188.	1.4	9
250	Quality and reporting of guidelines on the diagnosis and management of dystonia. European Journal of Neurology, 2018, 25, 275-283.	1.7	9
251	Trigeminal features in COVIDâ€19 patients with smell impairment. International Forum of Allergy and Rhinology, 2021, 11, 1253-1255.	1.5	9
252	Chronic administration of MPTP to monkeys: Behavioural morphological and biochemical correlates. Neurochemistry International, 1992, 20, 279-285.	1.9	8

#	Article	IF	Citations
253	Management of bladder, prostatic and pelvic floor disorders. Neurotoxicity Research, 2006, 9, 161-172.	1.3	8
254	Normal cardiovascular reflex testing in patients withparkin disease. Movement Disorders, 2007, 22, 528-532.	2.2	8
255	Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site. Parkinsonism and Related Disorders, 2021, 87, 70-74.	1.1	8
256	Development of a patient journey map for people living with cervical dystonia. Orphanet Journal of Rare Diseases, 2022, 17, 130.	1.2	8
257	FIXED DYSTONIA UNRESPONSIVE TO PALLIDAL STIMULATION IMPROVED BY MOTOR CORTEX STIMULATION. Neurology, 2007, 69, 1062-1063.	1.5	7
258	Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience. Parkinsonism and Related Disorders, 2021, 82, 146-149.	1.1	7
259	Oligophrenia with the Hallermann-Streiff syndrome. Journal of Neurology, 1979, 220, 211-214.	1.8	6
260	Histochemical Demonstration of Heavy Metals in the Reptilian Archicortex. International Journal of Neuroscience, 1985, 28, 11-19.	0.8	6
261	Discussion of unique properties of botulinum toxins. Toxicon, 2009, 54, 702-708.	0.8	6
262	Deep Brain Stimulation for Parkinson's Disease: Where Do We Stand?. Frontiers in Neurology, 2011, 2, 33.	1.1	6
263	No more mistaken identities for botulinum neurotoxins. Nature Reviews Neurology, 2016, 12, 373-374.	4.9	6
264	Motor and Sensory Features of Cervical Dystonia Subtypes: Data From the Italian Dystonia Registry. Frontiers in Neurology, 2020, 11, 906.	1.1	6
265	Advances in the genetics of primary torsion dystonia. F1000 Biology Reports, 2010, 2, .	4.0	6
266	Boxer disqualified for taking selegiline. Lancet, The, 1995, 346, 647.	6.3	5
267	Emerging Treatments in Parkinson's Disease. European Neurology, 1997, 38, 175-183.	0.6	5
268	Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists. Acta Neurologica Scandinavica, 2003, 107, 349-355.	1.0	5
269	Guest Editors' introduction. Movement Disorders, 2011, 26, S1-2.	2.2	5
270	Ambiguous idiom processing in Parkinson's disease patients. Cognitive Neuropsychology, 2013, 30, 495-506.	0.4	5

#	Article	IF	Citations
271	â€œComplexâ€•dystonia is not a category in the new 2013 consensus classification. Movement Disorders, 2016, 31, 1758-1759.	2.2	5
272	Impulse control behavior in GBA-mutated parkinsonian patients. Journal of the Neurological Sciences, 2021, 421, 117291.	0.3	5
273	Sudden Onset, Fixed Dystonia and Acute Peripheral Trauma as Diagnostic Clues for Functional Dystonia. Movement Disorders Clinical Practice, 2021, 8, 1107-1111.	0.8	5
274	Unsuspected, surreptitious drugâ€induced parkinsonism. Neurology, 1992, 42, 459-459.	1.5	5
275	A genetic study of neostriatal cholinergic neurones in C57BL/6 and DBA/2 mice. Functional Neurology, 1987, 2, 273-9.	1.3	5
276	The clinical diagnosis of multiple system atrophy presenting as pure parkinsonism. Advances in Neurology, 1996, 69, 393-8.	0.8	5
277	Letters to the Editor. Movement Disorders, 1998, 13, 980-982.	2.2	4
278	Apomorphine and levodopa challenge in patients with a focal midbrain lesion. Movement Disorders, 1999, 14, 269-275.	2.2	4
279	Unique properties of botulinum toxins. Toxicon, 2009, 54, 675.	0.8	4
280	Cell therapy for Parkinson's disease: have the glory days gone?. Lancet Neurology, The, 2011, 10, 492-493.	4.9	4
281	Reliability and Validity of the Range of Motion Scale (ROMS) in Patients with Abnormal Postures. Pain Medicine, 2015, 16, 488-493.	0.9	4
282	Functional gait disorders: Demographic and clinical correlations. Parkinsonism and Related Disorders, 2021, 91, 32-36.	1.1	4
283	Cholinergic-Monoaminergic Interactions in Selected Regions of the Brain: Histochemical and Pharmacologic Analyses. Advances in Behavioral Biology, 1981, , 723-738.	0.2	4
284	Clinical presentation and progression of sporadic and familial primary torsion dystonia in Italy. Advances in Neurology, 2004, 94, 171-8.	0.8	4
285	Gabapentin improved sensory and motor symptoms in the restless legs syndrome. ACP Journal Club, 2003, 139, 17.	0.1	4
286	Neuropeptides in dopamine-containing regions of the brain. Italian Journal of Neurological Sciences, 1984, 5, 391-404.	0.1	3
287	Transient alternating hemichorea as presenting sign of progressive supranuclear palsy. Italian Journal of Neurological Sciences, 1991, 12, 99-101.	0.1	3
288	Functional impairment of nigrostriatal neurons progresses following withdrawal of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience, 1996, 75, 1185-1191.	1.1	3

#	Article	IF	Citations
289	Can falls be prevented in Parkinson's disease?. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 661-661.	0.9	3
290	Emerging parkinsonian phenotypes. Revue Neurologique, 2010, 166, 834-840.	0.6	3
291	"Gluing" phenotypes together: The case of GLUT1. Neurology, 2011, 77, 934-935.	1.5	3
292	Adult diagnosis of Cockayne syndrome. Neurology, 2019, 93, 854-855.	1.5	3
293	Neurological research & training after the easing of lockdown in countries impacted by COVID-19. Journal of the Neurological Sciences, 2020, 418, 117105.	0.3	3
294	Design and Operation of the Lombardy Parkinson's Disease Network. Frontiers in Neurology, 2020, 11, 573.	1.1	3
295	Neuroimaging in idiopathic adult-onset focal dystonia. Neurological Sciences, 2021, 42, 2947-2950.	0.9	3
296	DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13â€“36.32 in an Italian family with cranial-cervical or upper limb onset. , 2001, 49, 362.		3
297	Clinical genetic study of familial Parkinson's disease in Italy. Advances in Neurology, 1999, 80, 181-6.	0.8	3
298	Dystonia in parkinsonian syndromes. Advances in Neurology, 2003, 91, 351-60.	0.8	3
299	The current status and use of botulinum toxins. European Journal of Neurology, 2001, 8, 3-7.	1.7	2
300	Cutaneous herpes zoster and implantable pulse generator. Neuromodulation, 2010, 13, 99-101.	0.4	2
301	Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: Need for longâ€term clinical trials. Movement Disorders, 2011, 26, 1370-1370.	2.2	2
302	Standard strategies for diagnosis and treatment of patients with newly diagnosed Parkinson disease. Neurology: Clinical Practice, 2013, 3, 476-477.	0.8	2
303	A 52â€Yearâ€Old Man with Myoclonic Jerks. Brain Pathology, 2016, 26, 291-292.	2.1	2
304	Prefrontal Cortical Stimulation in Tourette Disorder: Proofâ€ofâ€concept Clinical and Neuroimaging Study. Movement Disorders Clinical Practice, 2018, 5, 499-505.	0.8	2
305	Coronary embolization from aortic valve fibroelastoma. Clinical Case Reports (discontinued), 2020, 8, 1610-1612.	0.2	2
306	Deep Brain Stimulation in Dystonia: Disentangling Heterogeneity. Movement Disorders Clinical Practice, 2021, 8, 6-8.	0.8	2

#	Article	IF	Citations
307	Clinical Use of Botulinum Neurotoxin: Neuromuscular Disorders. , 2014, , 51-93.		2
308	Correlation of cardiovascular autonomic function tests, magnetic resonance brain imaging and clinical features in suspect cases of multiple system atrophy. Functional Neurology, 1991, 6, 269-73.	1.3	2
309	Chronic administration of MPTP to marmosets. Advances in Neurology, 1990, 53, 239-44.	0.8	2
310	Multiple System Atrophy-Reply. Archives of Neurology, 1996, 53, 212-213.	4.9	1
311	Gabapentin improved sensory and motor symptoms in the restless legs syndrome. Evidence-Based Medicine, 2003, 8, 117-117.	0.6	1
312	Botulinum Neurotoxin in Tremors, Tics, Hemifacial Spasm, Spasmodic Dysphonia, and Stuttering. , 2009, , 112-130.		1
313	Diagnostic issues in childhood and adult dystonia. Expert Opinion on Medical Diagnostics, 2011, 5, 483-500.	1.6	1
314	Early visual memory deficits. Neurology, 2012, 78, 1372-1373.	1.5	1
315	Dystonic Tremor. Contemporary Clinical Neuroscience, 2013, , 203-218.	0.3	1
316	Reply: Dystonia after severe head injuries. Movement Disorders, 2014, 29, 578-579.	2.2	1
317	Hyperkinesia, dystonia, and tics. , 0, , 291-300.		1
318	Management of sleep disorders in Parkinson's disease. , 0, , 151-161.		1
319	Autonomic dysfunction in Parkinson's disease associated with common glucocerebrosidase gene mutations. Parkinsonism and Related Disorders, 2016, 22, e26.	1.1	1
320	Parkinsonism and dysautonomia: Multiple system atrophy?. Parkinsonism and Related Disorders, 2020, 77, 146-149.	1.1	1
321	Chronic Administration of 1-Methyl-4-Phenyl-1,2,3,6- Tetrahydropyridine to Marmosets. Advances in Behavioral Biology, 1991, , 523-531.	0.2	1
322	Neuropsychiatric Disturbances in Dystonia. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 171-199.	0.3	1
323	Initial bromocriptine did not change mortality in early, mild Parkinson disease. Annals of Internal Medicine, 2002, 136, 109.	2.0	1
324	Clinical Features of Dystonia and European Guidelines for Diagnosis and Treatment. , 2007, , 3-9.		1

#	Article	IF	Citations
325	Attentional networks in Parkinson's disease. Behavioural Neurology, 2013, 27, 495-500.	1.1	1
326	Amyotrophic onset in GCH1 dopa-responsive dystonia. Iranian Journal of Neurology, 2019, 18, 181-183.	0.5	1
327	Nanotechnology and vascular neurosurgery: an in vivo experimental study on microvessels repair using laser photoactivation of a nanostructured hyaluronan solder. Journal of Biological Regulators and Homeostatic Agents, 2012, 26, 447-56.	0.7	1
328	Initial bromocriptine did not change mortality in early, mild Parkinson's disease. Evidence-Based Medicine, 2002, 7, 91-91.	0.6	0
329	Hypersalivation. , 0, , 201-228.		0
330	Clinical Trials of Botulinum Toxin in Adult Spasticity. , 2009, , 148-158.		0
331	Response to letter by Dr Neil Murray. European Journal of Neurology, 2011, 18, e62-e62.	1.7	0
332	Reply to Dr MichaudetÂal.. European Journal of Neurology, 2015, 22, e78-e78.	1.7	0
333	Tics and Tremors. , 2015, , 743-750.		0
334	Sirkka-Liisa Leinonen. European Journal of Neurology, 2016, 23, 673-674.	1.7	0
335	Editorial: Toxins 2017. Toxicon, 2016, 123, S1.	0.8	0
336	Editorial: Unmet Needs in Dystonia. Frontiers in Neurology, 2017, 8, 197.	1.1	0
337	Management algorithm for BoNT injections with electromyography and ultrasound guidance in cervical dystonia. Toxicon, 2018, 156, S14-S15.	0.8	0
338	Patient-centred management of Parkinson's disease. Lancet Neurology, The, 2020, 19, 888-889.	4.9	0
339	Cueing brain rhythms in Parkinsonâ€™s disease. Clinical Neurophysiology, 2021, 132, 2675-2676.	0.7	0
340	Botulinum Neurotoxin Revisited â€“ An Individualised, Patient-centric Approach for the Treatment of Dystonia and Spasticity. European Neurological Review, 2015, 10, 28.	0.5	0
341	Suprasegmental control of vegetative nervous system. Functional Neurology, 1987, 2, 407-16.	1.3	0
342	Biochemical differences between the left and right hemispheres. Preliminary observations on choline acetyl transferase (CAT) activity. Bollettino Della SocietÃ Italiana Di Biologia Sperimentale, 1980, 56, 2266-70.	0.0	0

#	Article	IF	Citations
343	New delivery systems for antiparkinsonian drugs. Advances in Neurology, 1999, 80, 549-54.	0.8	0
344	Review: several drugs are efficacious for symptomatic treatment of Parkinson disease. ACP Journal Club, 2003, 138, 14.	0.1	0
345	Review: Several drugs are efficacious for symptomatic treatment of Parkinson disease. ACP Journal Club, 2003, 138, 14.	0.1	0